Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering

OKLAHOMA CITY, Nov. 30, 2022 /PRNewswire/ — Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of mammalian-expressed protein therapeutics, today announced it has been granted a license to ATUM’s proprietary Leap-In Transposase® and miCHO™ cell line development technology.

https://www.prnewswire.com/news-releases/wheeler-bio-licenses-atums-proprietary-leap-in-transposase-technology-in-support-of-its-disruptive-cdmo-service-offering-301689682.html